Post-transplant hyperlipidemia: Mechanisms and management

Z. A. Massy, Bert L Kasiske

Research output: Contribution to journalReview articlepeer-review

85 Scopus citations


Hyperlipidemia is common after renal transplantation. In recent years, much progress has been made in understanding the causes and treatment of lipid abnormalities in renal transplant patients. Recently, short-term studies have shown that newer antilipemic agents appear to be safe and effective in treating hyperlipidemia in this population. Despite the absence of large, controlled clinical trials examining the effect of lipid-lowering strategies on cardiovascular disease and chronic renal allograft rejection, therapy appears to be warranted in renal transplant patients with an atherogenic lipid profile and multiple risk factors.

Original languageEnglish (US)
Pages (from-to)971-977
Number of pages7
JournalJournal of the American Society of Nephrology
Issue number7
StatePublished - Dec 1 1996


  • Cholesterol
  • Coronary heart disease
  • Graft rejection
  • Kidney transplantation
  • Triglycerides


Dive into the research topics of 'Post-transplant hyperlipidemia: Mechanisms and management'. Together they form a unique fingerprint.

Cite this